Crispr

The first patient has been treated in a phase 1/2 trial of AGN-151587, the first in vivo CRISPR medicine to be administered in patients, according to a press release from Editas Medicine.

A study presented at the American Society of Hematology’s Meeting and Exposition found that cells genetically edited using CRISPR/Cas9 technology and infused back into patients with multiple myeloma and sarcoma appeared safe and feasible. This was among the week’s top stories in hematology/oncology.

ORLANDO — Immune cells genetically edited with CRISPR/Cas9 technology and infused back into patients with multiple myeloma and sarcoma appeared to be safe and represent a feasible therapeutic approach, according to results of a prospective phase 1 study presented at ASH Annual Meeting and Exposition.